Investors weren't impressed with Bristol-Myers Squibb Company's (BMY) Q2 2025 results, with the stock down by 5.8% after ...

Bristol-Myers Squibb reported second-quarter earnings that exceeded analyst expectations, driven by strong performance across ...

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading ...

A new café opening in the Downtown Grand Rapids Market will offer everything from a cheese counter and wine bar to coffee and ...

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...

Type II cryoglobulinemic vasculitis in patients with Sjögren disease is associated with nearly a sevenfold increased risk for lymphoma and death in a study.

PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.

After beating AstraZeneca’s Calquence in quarterly revenue for the first time at the end of 2024, BeOne Medicines’ Brukinsa ...

Business advice guru Squibb, for whom Hong Kong played a special part is his story, talks about helping people gain financial ...